Recently, Vallo et al. [47] conducted a meta-analysis of four studies to explore the association between the PPARG Pro12Ala polymorphism and response to TZD treatment in T2DM patients, utilizing FPG and HbA1C as outcomes. Here, PPARG is linked to type 2 diabetes mellitus.